Watson Rebecca’s Ionis Pharmaceuticals IONS Stock Holding History

Watson Rebecca’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75	Closed	-$4K	–	212
2020 Q2	$4K	Buy	+75	New	+$4.17K	﹤0.01%	314

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Watson Rebecca's IONS Position: Q3 2020 in Review

Watson Rebecca sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 75 shares — an estimated $4K sold.

Watson Rebecca first reported a position in IONS in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

Watson Rebecca reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Watson Rebecca sold 75 Ionis Pharmaceuticals shares in Q3 2020, an estimated $4K.
Watson Rebecca first reported a position in Ionis Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Watson Rebecca's Ionis Pharmaceuticals position peaked at $4K in Q2 2020.
367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Watson Rebecca's 13F filing for Q3 2020, filed 22 Oct 2020.